Pronounce: TRIP-toe-REL-in
Classification: Luteinizing Hormone Releasing Hormone (LHRH) Agonist
Triptorelin is a type of Luteinizing Hormone-Releasing (LHRH) agonist. Most prostate cancers need supplies of the male hormone testosterone to grow. Testosterone is an androgen produced by the testes and adrenal glands. The production of testosterone can be stopped by surgically removing the testicles or through medication therapy. A hormone called luteinizing hormone (LH), which is produced by the pituitary gland stimulates the production of testosterone by the testicles. Agonists of the LH releasing hormone (i.e. LHRH agonists) stop the production of luteinizing hormone by the pituitary gland. This reduces the production of testosterone in men. The cancer cells may then grow more slowly or stop growing altogether.
Triptorelin is given as an intramuscular (IM, into the muscle) injection at your healthcare provider’s office. Triptorelin is given once every 4, 12, or 24 weeks, depending on the dose. It is usually injected into the buttock, rotating the injection site with each injection.
There are a number of things you can do to manage the side effects of triptorelin. Talk to your care team about these recommendations. They can help you decide what will work best for you. These are some of the most common or important side effects:
When starting an LHRH agonist, the body initially has a temporary increase in testosterone levels. This "flare" can lead to a temporary increase in the tumor size, causing symptoms related to the cancer to worsen. Your healthcare team can tell you what to look for in your particular case and the treatment necessary. The symptoms typically diminish 3 to 4 weeks after your injection was given.
There are a few things you can do to help with hot flashes. Several medications have been shown to help with symptoms, including clonidine (a blood pressure medication), low doses of certain antidepressants (such as venlafaxine and fluoxetine), and gabapentin. Talk to your healthcare team about these prescription products to determine if they are right for you.
Non-medical recommendations include:
Men who take hormone therapy for extended periods of time are at risk for bone thinning (osteoporosis). You may be advised to take calcium and vitamin D supplements to help prevent bone loss. Weight-bearing exercise and a healthy diet rich in calcium and vitamin D can also help protect your bone health. You may have a bone density scan (DEXA scan) to assess your bone health. If your physician determines that you are at high risk of developing osteoporosis, they may recommend additional treatment with a type of medication called a bisphosphonate to help strengthen the bones.
These side effects typically go away once the medication is stopped. You may notice a lack of ability to have and maintain an erection, loss of sex drive, or a decrease in the size of the testicles. Talk to your healthcare team about options to treat these symptoms.
An increase in breast tissue (gynecomastia) or breast tenderness may develop. Your healthcare team can suggest medications to relieve the tenderness. In rare cases, radiation can be given to relieve the tenderness.
Fatigue is very common during cancer treatment and is an overwhelming feeling of exhaustion that is not usually relieved by rest. While on cancer treatment, and for a period after, you may need to adjust your schedule to manage fatigue. Plan times to rest during the day and conserve energy for more important activities. Exercise can help combat fatigue; a simple daily walk with a friend can help. Talk to your healthcare team for helpful tips on dealing with this side effect.
Exposure of an unborn child to this medication could cause birth defects, so you should not father a child while on this medication. Effective birth control is necessary during treatment. Even if you believe you are not producing sperm, you could still be fertile.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2025 Trustees of The University of Pennsylvania